TriggerFinger


Regeneron antibody treatment produces long lasting immunity


ReutersRegeneron Pharmaceuticals Inc (REGN.O) said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in a late-stage trial, in the two to eight months period following the drug's administration.

The antibody therapy, REGEN-COV, is currently authorized in the United States to treat people with mild-to-moderate COVID-19 and for prevention of infection in those exposed to infected individuals, and others at high risk of exposure in settings such as nursing homes or prisons

Credible and effective treatments should render any vaccine mandates null and void.

This entry was published Sun Nov 21 23:32:57 CST 2021 by TriggerFinger and last updated 2021-11-21 23:32:57.0. [Tweet]

comments powered by Disqus

Related Categories


Subscribe to Atom Feed

I am not a lawyer, and nothing on this site should be taken as legal advice.

This site is run on custom blog software and is being actively developed. Please be forgiving of errors.


This website is an Amazon affiliate and will receive financial compensation for products purchased from Amazon through links on this site.